Deerfield Management Co Lowers stake in Xencor Inc (XNCR)

Xencor Inc (XNCR) : Deerfield Management Co reduced its stake in Xencor Inc by 24.56% during the most recent quarter end. The investment management company now holds a total of 2,210,900 shares of Xencor Inc which is valued at $56,820,130 after selling 719,586 shares in Xencor Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Xencor Inc makes up approximately 3.23% of Deerfield Management Co’s portfolio.

Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in XNCR in the latest quarter, The investment management firm added 300,360 additional shares and now holds a total of 875,676 shares of Xencor Inc which is valued at $22,504,873.Vident Investment Advisory reduced its stake in XNCR by selling 666 shares or 1.37% in the most recent quarter. The Hedge Fund company now holds 47,916 shares of XNCR which is valued at $1,074,756. Xencor Inc makes up approx 0.14% of Vident Investment Advisory’s portfolio. Matarin Capital Management added XNCR to its portfolio by purchasing 13,428 company shares during the most recent quarter which is valued at $298,907. Xencor Inc makes up approx 0.03% of Matarin Capital Management’s portfolio. Dupont Capital Management Corp added XNCR to its portfolio by purchasing 15,194 company shares during the most recent quarter which is valued at $311,629. Xencor Inc makes up approx 0.01% of Dupont Capital Management Corp’s portfolio.Acadian Asset Management boosted its stake in XNCR in the latest quarter, The investment management firm added 292,178 additional shares and now holds a total of 361,540 shares of Xencor Inc which is valued at $7,393,493. Xencor Inc makes up approx 0.04% of Acadian Asset Management’s portfolio.

Xencor Inc opened for trading at $26.92 and hit $27.38 on the upside on Monday, eventually ending the session at $26.8, with a gain of 0.07% or 0.02 points. The heightened volatility saw the trading volume jump to 1,84,731 shares. Company has a market cap of $1,103 M.

Many Wall Street Analysts have commented on Xencor Inc. Xencor Inc was Initiated by Piper Jaffray to “Overweight” on Oct 4, 2016.

Xencor Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases cancer and other conditions. The Company’s product pipeline includes three lead XmAb-engineered antibodies which include XmAb5871 XmAb7195 and XmAb5574/MOR208. XmAb5871 is indicated for the treatment of moderate-to-severe rheumatoid arthritis. XmAb7195 is the Company’s wholly owned program being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers.

Leave a Reply

Xencor Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Xencor Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.